cancer deck2

Question 1

bevacizumab mechanism

Answer 1

monoclonal antibody against VEGF; inhibits angiogensis (BeVacizumab inhibits Blood Vessel formation)

Question 2

use of bevaciuzmab

Answer 2

solid tumors (colorectal, rcc)

Question 3

se of bevacizumab

Answer 3

hemorraghe, blood clots , impiared wound healing

Question 4

erlotinib

Answer 4

egfr tyrosine kinase inhibitor

Question 5

use of erlotinib

Answer 5

non small cell lung carcinoma

Question 6

SE of erlotinib

Answer 6

rash

Question 7

cetuximab mechanism

Answer 7

monoclonal antibody against EGFR

Question 8

use of cetuximab

Answer 8

Stage IV colorectal cancer (wild type KRAS); head and neck cancer

Question 9

se of cetuximab

Answer 9

rash, elevated LFT’s; diarrhea

Question 10

imatinib mechanism

Answer 10

tyrosine kinase inhibotr of BCR-ABL and c-kit

Question 11

use of imatinib

Answer 11

CML, GI stromal tumors

Question 12

SE of imatininb

Answer 12

fluid reteion

Question 13

rituximab

Answer 13

monoclonal antibody against CD20 which is found on most B cell neoplasms

Question 14

clinical use of rituximab

Answer 14

NHL, CLL, ITP, RA

Question 15

se of rituximab

Answer 15

increase risk of progressive mutlifocal leukoencepahtloty

Question 16

bortezomib, carfilzomib mechanism

Answer 16

proteasome inhibitors, induce arrest at G2-M phase and apoptosis

Question 17

use of bortezomib, carfilzomib

Answer 17

multiple myeloma, mantle cell lymphoma

Question 18

SE of bortezomib, carfilzomib

Answer 18

peripheral neuropathy, herpes zoster reactivation

Question 19

vemurafenib

Answer 19

small molecule inhibotor of BRAF oncogene + melaonma. (use in metastatic melanoma)

Question 20

trastuzumab )herceptin

Answer 20

monoclonal antibody against HER 2 (c-erbB2); a tyrosine kinase receptor
helps kill cancer cells that overexpress HER-2, through inhibition of HER2-initiated cellular signaling and antibody depednent cytotoxcity

Question 21

trastuzumab use

Answer 21

HER2 breast cancer, and gastric cancer

Question 22

SE of trastuzumab

Answer 22

cardiotoxicty

Question 23

tamoxifen, raloxifene mechainsm

Answer 23

selective estrogen receptor modulaters (SERMs) - receptor antagonists in breast and agonists in bone; block binding of estrogen to ER + cells

Question 24

use of taomxidfen raloxifene

Answer 24

breast cancer treatment (tamoxifen) and prevention.

raloxifene prevente osteoporsis

Question 25

SE of tamoxifen

Answer 25

partial agonist in endometrium; increase risk of endometrial carncer; hot flashes

Question 26

raloxifene SE

Answer 26

no increase in endometrial carcinoma; bc it is an estrogen receptor antagnoist in endometrial tissue

Question 27

tamoxifen and raloxifene se

Answer 27

both increase rsik of thromboemobolic envets

Question 28

phosphate binder to manage hyperphosphatemia in tumor lysis syndrome

Answer 28

sevelamer

Question 29

K+ exhcange resins

Answer 29

sodium polystyrene sulfonate

Question 30

rasburicase mechanism

Answer 30

recombinant uricase that catalyzes metabolism of uric acid to allantoin

Question 31

use of rasburicase

Answer 31

prevention and treamtnte of tumor lyssi sydnrome

Question 32

podophyllin:

Answer 32

inhibits topoII; treats genital warts2w

Question 33

aminocaproic acid

Answer 33

anti fibrinolytic med to treat extensive post op bleeding

Question 34

gardos channel blocker mechanism

Answer 34

hinders efflux of potassium and water from cell. preventing degradation of erythrocytes and reducing polymerization of hbs